{'52WeekChange': 9.8412695,
 'SandP52WeekChange': None,
 'address1': '3530 John Hopkins Court',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 13.22,
 'askSize': 4000,
 'averageDailyVolume10Day': 1206725,
 'averageVolume': 2515569,
 'averageVolume10days': 1206725,
 'beta': 3.131825,
 'beta3Year': None,
 'bid': 13.2,
 'bidSize': 1400,
 'bookValue': 1.042,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Diego',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 13.59,
 'dayLow': 12.51,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -21.89,
 'enterpriseToRevenue': 21650.469,
 'enterpriseValue': 1277377664,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 11.086,
 'fiftyTwoWeekHigh': 15.7,
 'fiftyTwoWeekLow': 1.04,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 35974486,
 'forwardEps': -0.8,
 'forwardPE': -16.55,
 'fromCurrency': None,
 'fullTimeEmployees': 153,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.71733004,
 'heldPercentInstitutions': 0.05994,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1345161600,
 'lastSplitFactor': '8:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/nantkwest.com',
 'longBusinessSummary': 'NantKwest, Inc., a clinical-stage immunotherapy '
                        'company, develops immunotherapeutic treatments for '
                        'cancer and viral infectious diseases in the United '
                        'States. The company develops activated natural killer '
                        '(aNK) cell, a natural killer cell-line and '
                        'genetically modified derivative capable of killing '
                        'cancer and virally infected cells; and Nant cancer '
                        'vaccine, a personalized therapy that utilizes its '
                        'off-the-shelf natural killer cells. It is also '
                        'developing high-affinity natural killer (haNK) '
                        'product candidates primarily for the treatment of '
                        'various cancers; and tank and t-haNK product '
                        'candidates to treat solid tumors. NantKwest, Inc. has '
                        'a co-development agreement with Altor BioScience, LLC '
                        'to collaborate on the development of therapeutic '
                        "applications combining the company's proprietary "
                        "natural killer cells with Altor's N-801 and/or N-803 "
                        'products; collaboration with Be The Match '
                        'BioTherapies for the development of cell therapy to '
                        'prevent COVID-19 deaths; and strategic alliance with '
                        'Immunitybio. The company was formerly known as '
                        'Conkwest, Inc. and changed its name to NantKwest, '
                        'Inc. in July 2015. NantKwest, Inc. was founded in '
                        '2002 and is headquartered in San Diego, California.',
 'longName': 'NantKwest, Inc.',
 'market': 'us_market',
 'marketCap': 1417077120,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_262241549',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -66287000,
 'nextFiscalYearEnd': 1640908800,
 'open': 13.49,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 12.55,
 'phone': '858-633-0300',
 'previousClose': 13.66,
 'priceHint': 2,
 'priceToBook': 12.706333,
 'priceToSalesTrailing12Months': 24018.256,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 13.59,
 'regularMarketDayLow': 12.51,
 'regularMarketOpen': 13.49,
 'regularMarketPreviousClose': 13.66,
 'regularMarketPrice': 13.49,
 'regularMarketVolume': 1051033,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 107030000,
 'sharesPercentSharesOut': 0.0506,
 'sharesShort': 5416829,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4305289,
 'shortName': 'NantKwest, Inc.',
 'shortPercentOfFloat': 0.1463,
 'shortRatio': 1.49,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'NK',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.673,
 'twoHundredDayAverage': 6.3692446,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '93437597-656e-3db3-8497-6096b6261386',
 'volume': 1051033,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.nantkwest.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92121'}